ATG9A and cancer: Over 6 weeks, we observed a robust reduction in the growth of ATG9A KO tumors as compared to control tumors when treated with Trastuzumab, demonstrating that ATG9A ablation sensitizes SKOV-3 cancer cells to macrophage-mediated killing induced by Trastuzumab; no growth difference was observed in human IgG isotype group, indicating that ATG9A KO did not impact baseline cell proliferation or survival in vivo (Fig. 3B).